Evercore ISI analyst Elizabeth Anderson CFA reiterated a Buy rating on McKesson (MCK – Research Report) yesterday and set a price target of ...

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

McKesson (MCK) concluded the recent trading session at $585.08, signifying a +0.57% move from its prior day's close.

Cardinal Health’s profit margin lags behind peers, impacting growth. See why CAH stock’s outlook may be hindered by legal ...

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on McKesson (MCK – Research Report), with a price target of ...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall ...

From research on new weight-loss drugs to the impact of artificial intelligence (AI) in medicine, 2024 has been marked by important scientific advances, especially in health. Euronews Health ...